from24/7 Wall St.
3 days agoBofA Raises Hims & Hers Target to $25 as FDA Takes a Step Toward Wellness Peptides: Is a New Revenue Boom Coming?
Bank of America raised its price target on Hims & Hers to $25 from $21, maintaining a Neutral rating. The FDA's procedural step to evaluate wellness peptides could open new revenue doors for the telehealth platform.
Healthcare











